Day One Biopharmaceuticals, Inc , a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers.
infoDay One Biopharmaceuticals is a small cap stock with a total market cap of 1.18B.
infoThey trade on the NASDAQ and had their IPO 2 years and 2 months ago.
infoDay One Biopharmaceuticals currently employs 124 people.
infoAs of Wednesday, Aug 23 2023, Day One Biopharmaceuticals’s share price is $13.51.
News Relating to Day One Biopharmaceuticals
Seeking Alpha
Diving Into Day One Biopharmaceuticals
Sunday Jul 23 2023 at 04:43
Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis’ combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to treat all BRAF-mutated pLGG patients, whereas Novartis’ combo only addresses about 10% to 20% of that population. With tovorafenib’s somewhat risky rolling NDA submission slated for October 2023 and ample cash for commercialization, the recent beneficial owner buying merited a look into this busted IPO.
The Motley Fool
Why Shares of Day One Pharmaceuticals Are Up Monday
Monday Jun 05 2023 at 12:30
Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The company said the drug showed a high overall response rate on heavily pretreated patients with a type of brain tumor.
Market Watch
Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment
Monday Jun 05 2023 at 08:09
Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigational treatment for relapsed or progressive pediatric low-grade glioma. Trial data showed high rates of durable tumor reduction and a safety profile that allows for potential long-term dosing, the company said in a release.
Proactive Investors
Day One Biopharmaceuticals stock rallies as 1Q results show the brain tumor treatment candidate producer is funded into 2025
Monday May 01 2023 at 14:39
Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results. The Brisbane, California company reported a cash position of $318.2 million as of March 31, which management believes is sufficient to fund operations into 2025.
Seeking Alpha
Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns
Friday Apr 07 2023 at 07:37
Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial years.
GlobeNewsWire
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
Tuesday Dec 20 2022 at 08:00
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.
Seeking Alpha
Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sunday Sep 04 2022 at 12:17
Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position.
GlobeNewsWire
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Tuesday Aug 02 2022 at 08:00
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye – Targeted Oncology – Finding Needles in Plain Sight” will be held on Tuesday, August 9 at 10:55 a.m. ET.
Zacks Investment Research
Biotech ETF Tops in June: 5 Stocks That Outperform
Thursday Jun 30 2022 at 14:52
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders’ “short squeeze” and investors’ bargain hunting.
The Motley Fool
Here’s How Day One Biopharmaceuticals Stock Could Keep Climbing
Wednesday Jun 15 2022 at 05:41
A giant run-up on Monday could be the beginning of a much larger bull run.
InvestorPlace
Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?
Monday Jun 13 2022 at 13:56
Today’s announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?
Benzinga
Why Day One Biopharma Shares Are Surging Today
Monday Jun 13 2022 at 08:10
Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children. .
GlobeNewsWire
Day One to Present at the 21st Annual Needham Virtual Healthcare Conference
Wednesday Apr 06 2022 at 08:30
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET.
GlobeNewsWire
Day One Appoints Jaa Roberson as Chief People Officer
Monday Sep 13 2021 at 07:00
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa Roberson as chief people officer. In her role, Ms. Roberson will oversee all aspects of Day One’s human resources and talent acquisition efforts.
GlobeNewsWire
Day One Appoints Scott Garland to Board of Directors
Tuesday Aug 17 2021 at 07:00
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Company’s board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience.
GlobeNewsWire
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
Tuesday Aug 10 2021 at 16:05
DAY101 Granted Rare Pediatric Disease Designation from FDA
GlobeNewsWire
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
Monday Jun 21 2021 at 07:00
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.
GlobeNewsWire
Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Tuesday Jun 01 2021 at 16:01
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares were offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, were $184.0 million. The shares began trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.”
Seeking Alpha
U.S. IPO Weekly Recap And Week Ahead
Saturday May 29 2021 at 23:23
U.S. IPO Weekly Recap And Week Ahead
GlobeNewsWire
Day One Announces Pricing of Upsized Initial Public Offering
Wednesday May 26 2021 at 22:30
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.” The offering is expected to close on June 1, 2021, subject to the satisfaction of customary closing conditions. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Market Watch
Day One Biopharmaceuticals upsizes IPO to 10 million shares from 8.4 million
Wednesday May 26 2021 at 06:47
Day One Biopharmaceuticals Inc. , which specializes in developing cancer treatments for children, upsized its initial public offering on Wednesday to 10 million shares from a previous plan to offer 8.4 million. The company is still proposing a price range of $14 to $16 a share.
Day One Biopharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Day One Biopharmaceuticals’s Altman Z-score is 27.26 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Day One Biopharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 3 insiders have sold $63.56K of common stock in Day One Biopharmaceuticals on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Day One Biopharmaceuticals’s Income Quality of 0.5 is lower than its Industry Group of 0.69 (-27.5% lower)
Day One Biopharmaceuticals’s Income Quality of 0.5 is lower than its Major Industry Group of 0.71 (-29.6% lower)
Day One Biopharmaceuticals’s Income Quality of 0.5 is lower than its Sector of 0.75 (-33.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Day One Biopharmaceuticals’s Current Ratio of 18.35 is greater than its Industry Group of 4.76 (285.5% greater)
Day One Biopharmaceuticals’s Current Ratio of 18.35 is greater than its Major Industry Group of 4.32 (324.8% greater)
Day One Biopharmaceuticals’s Current Ratio of 18.35 is greater than its Sector of 2.6 (605.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-7.83 & -1.27)
Cannot compare a negative PE Ratio (-7.83 & -1.1)
Cannot compare a negative PE Ratio (-7.83 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Day One Biopharmaceuticals’s PB Ratio of 2.76 is greater than its Industry Group of 1.34 (106.0% greater)
Day One Biopharmaceuticals’s PB Ratio of 2.76 is greater than its Major Industry Group of 1.4 (97.1% greater)
Day One Biopharmaceuticals’s PB Ratio of 2.76 is greater than its Sector of 1.62 (70.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Day One Biopharmaceuticals’s ROE of -0.35 is greater than its Industry Group of -0.44 (20.5% greater)
Day One Biopharmaceuticals’s ROE of -0.35 is in line with its Major Industry Group of -0.38 (7.9% greater)
Day One Biopharmaceuticals’s ROE of -0.35 is lower than its Sector of -0.03 (-1066.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Day One Biopharmaceuticals’s ROCE of -0.42 is in line with its Industry Group of -0.42
Day One Biopharmaceuticals’s ROCE of -0.42 is lower than its Major Industry Group of -0.37 (-13.5% lower)
Day One Biopharmaceuticals’s ROCE of -0.42 is lower than its Sector of -0.04 (-950.0% lower)
Derived from SEC.GOV filing dataopen_in_new